A recent report from Goldman Sachs, featured in an article on News Max Finance strongly indicates that regenerative medicine is continuing to be a an attractive option for investment.
The GS report is entitled “The Coming Age of Regenerative Medicine”, and to quote from it “venture capital in companies pursuing regenerative medicine increased from $296 million in 2011 to $807 million in 2016, growing roughly 34% year-over-year.”
The report also states that 80 regenerative-medicine companies have gained investment with the last 3 years, representING approximately 50% of the top VC deals in 2015 and 2016.
Grace Century President and Director of Research Scott Wolf said “This continues to show that our research was right 6 years ago. Regenerative medicine is the new Gold Rush.”